Creation of a zymogen

Nature Structural Biology

Volumn 10, Issue 2, 2003, Pages 115-119

  Plainkum, Parit ^a,b   Fuchs, Stephen M ^a   Wiyakrutta, Suthep ^b   Raines, Ronald T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Mahidol University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ENZYME PRECURSOR; PLASMEPSIN II; RIBONUCLEASE A;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME STABILITY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ASPARTIC ENDOPEPTIDASES; CATALYTIC DOMAIN; CATTLE; ENZYME ACTIVATION; ENZYME PRECURSORS; ENZYME STABILITY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PLASMIDS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; RIBONUCLEASE, PANCREATIC;

PLASMODIUM FALCIPARUM;

EID: 0037313263     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsb884     Document Type: Article

References (34)

1. Von Der Helm, K., Korant, B.D. & Cheronis, J.C. Proteases as Targets for Therapy. (Springer-Verlag, Heidelberg; 2000).
2. Smith, J. & Simons, C. Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. (Taylor & Francis, London; 2002).
3. Kühne, W. Ueber die verdauung der eiweissstoffe durch den pankreassaft. Virchows Arch. 39, 130-174 (1867).
4. Khan, A.R. & James, M.N.G. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 7, 815-836 (1998).
5. Laskowski, M. Jr., Qasim, M.A. & Lu, S.M. Interaction of standard mechanism, canonical protein inhibitors with serine proteases, in Protein-Protein Recognition (ed. Kleanthous, C.) 228-279 (Oxford University Press, Oxford; 2000).
6. Lazure, C. The peptidase zymogen proregions: Nature's way of preventing undesired activation and proteolysis. Curr. Pharm. Des. 8, 509-529 (2002).
7. Leland, P.A. & Raines, R.T. Cancer chemotherapy - ribonucleases to the rescue. Chem. Biol. 8, 405-413 (2001).
8. Kleanthous, C. & Pommer, A.J. Nuclease inhibitors, in Protein-Protein Recognition (ed. Kleanthous, C.) 280-311 (Oxford University Press, Oxford; 2000).
9. D'Alessio, G. & Riordan, J.F. Ribonucleases: Structures and Functions. (Academic Press, New York; 1997).
10. Raines, R.T. Ribonuclease A. Chem. Rev. 98, 1045-1065 (1998).
11. Goldenberg, D.P. & Creighton, T.E. Circular and circularly permuted forms of bovine pancreatic trypsin inhibitor. J. Mol. Biol. 165, 407-413 (1983).
12. Todd, A.E., Orengo, C.A. & Thornton, J.M. Plasticity of enzyme active sites. Trends Biochem. Sci. 27, 419-426 (2002).
13. Grishin, N.V. Fold change in evolution of protein structures. J. Struct. Biol. 134, 167-185 (2001).
14. Silva, A.M. et al. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 93, 10034-10039 (1996).
15. Klemba, M. & Goldberg, D.E. Biological roles of proteases in parasitic protozoa. Annu. Rev. Biochem. 7, 275-305 (2002).
16. Goldberg, D.E. et al. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. 173, 961-969 (1991).
17. Francis, S.E., Sullivan, D.J. Jr. & Goldberg, D.E. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. Rev. Microbiol. 51, 97-123 (1997).
18. Francis, S.E., Banerjee, R. & Goldberg, D.E. Biosynthesis and maturation of the malaria aspartic hemoglobinases plasmepsins I and II. J. Biol. Chem. 272, 14961-14968 (1997).
19. Bernstein, N.K., Cherney, M.M., Loetscher, H., Ridley, R.G. & James, M.N. Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from Plasmodium falciparum. Nat. Struct. Biol. 6, 32-37 (1999).
20. Klink, T.A. & Raines, R.T. Conformational stability is a determinant of ribonuclease A cytotoxicity. J. Biol. Chem. 275, 17463-17467 (2000).
21. delCardayré, S.B. et al. Engineering ribonuclease A: production, purification, and characterization of wild-type enzyme and mutants at G?n11. Protein Eng. 8, 261-273 (1995).
22. Leland, P.A., Schultz, L.W., Kim, B.M. & Raines, R.T. Ribonuclease A variants with potent cytotoxic activity. Proc. Natl. Acad. Sci. USA 95, 10407-10412 (1998).
23. Parsell, D.A. & Sauer, R.T. The structural stability of a protein is an important determinant of its proteolytic susceptibility in Escherichia coli. J. Biol. Chem. 264, 7590-7595 (1989).
24. Bretscher, L.E., Abel, R.L. & Raines, R.T. A ribonuclease A variant with low catalytic activity but high cytotoxicity. J. Biol. Chem. 275, 9893-9896 (2000).
25. Fawell, S. et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91, 664-668 (1994).
26. Haigis, M.C., Kurten, E.L., Abel, R.L. & Raines, R.T. KFERQ sequence in ribonuclease A-mediated cytotoxicity. J. Biol. Chem. 277, 11576-11581 (2002).
27. Leland, P.A., Staniszewski, K.E., Kim, B.M. & Raines, R.T. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J. Biol. Chem. 276, 43095-43102 (2001).
28. Mikulski, S.M. et al. Phase II trial of a single weekly intravenous does of ranpirnase in patients with unresectable malignant mesothelioma. J. Clin. Oncol. 20, 274-281 (2002).
29. Wlodawer, A., Svensson, L.A., Sjölin, L. & Gilliland, G.L. Structure of phosphate-free ribonuclease A refined at 1.26 Å. Biochemistry 27, 2705-2717 (1988).
30. Westling, J. et al. Plasmodium falciparum, P. vivax and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite. Exp. Parasitol. 87, 185-193 (1997).
31. Hill, J. et al. High level expression and characterisation of Plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett. 352, 155-158 (1994).
32. Kelemen, B.R. et al. Hypersensitive substrate for ribonucleases. Nucleic Acids Res. 27, 3696-3701 (1999).
33. Klink, T.A., Woycechowsky, K.J., Taylor, K.M. & Raines, R.T. Contribution of disulfide bonds to the conformational stability and catalytic activity of ribonuclease A. Eur. J. Biochem. 267, 566-572 (2000).
34. Westling, J. et al. Active site specificity of plasmepsin II. Protein Sci. 8, 2001-2009 (1999).